Brief: Calidi Biotherapeutics NYSE American To Commence Delisting Proceedings With Respect To Warrants Of Co
18/10/2024 22:28
Oct 18 (Reuters) - Calidi Biotherapeutics Inc CLDI.A :
* CALIDI BIOTHERAPEUTICS: NYSE AMERICAN TO COMMENCE
DELISTING
PROCEEDINGS WITH RESPECT TO WARRANTS OF CO
Source text for Eikon: ID:n0001493152-24-041623
Further company coverage: CLDI.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Calidi Biotherapeutics
See all newsBrief: Calidi Biotherapeutics Announces Strategic Partnership With Transferai
Brief: Calidi Biotherapeutics Announces Partnership With Avance Clinical To Facilitate Australian Regulatory Approval
Brief: Calidi Biotherapeutics Announces Pricing Of $5.2 Million Underwritten Public Offering
Brief: Calidi Biotherapeutics Eliminates Chief Legal Officer Position - SEC Filing
Brief: Calidi Biotherapeutics Receives FDA Fast Track Designation For Cld-201 (Supernova), A First-In-Class Stem-Cell Loaded Viral Therapy For The Treatment Of Patients With Soft Tissue Sarcoma